An interventional study of Inspiratory Muscle Training and Functional Inspiratory Muscle Training in Congenital Heart Disease, Telerehabilitation and Functional Inspiratory Muscle Training, sponsored by Izmir Democracy University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 8 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Izmir Democracy University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Heart Defects, Congenital with a site in Turkey — 11 open to participants now, 12 under way, none of them phase 3. Heart Defects, Congenital · Turkey.
Among the 32 studies in Heart Defects, Congenital with a site in Turkey, this one is the 17th largest by planned enrollment of the 18 interventional ones that give a count, is one of 5 that started in 2026, is one of 17 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 32nd registered.
992 studies on the registry are indexed under Heart Defects, Congenital; 252 are open to participants now.
Browse Heart Defects, Congenital studies →11 of the 32 studies in Heart Defects, Congenital with a site in Turkey are open now. Recruiting first, the newest first:
Baskent University · Sites in Turkey
Ages 2 mo–12 mo
Fondation Hôpital Saint-Joseph · Sites in Turkey, Denmark, Egypt and 14 more countries
Ages 1 mo+
Ankara Yildirim Beyazıt University · Sites in Turkey
Ages 16–20
Hacettepe University · Sites in Turkey
Ages 8–55 · Healthy volunteers
Occlutech International AB · Sites in Turkey, Ireland, United Kingdom
Ages 3 mo–80 yrs
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 156 Heart Defects, Congenital studies recruiting now, 69 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 112 take children under 18; 25 take healthy volunteers.
This study: 8 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 32 is below the median of 60 across 508 interventional studies indexed under Heart Defects, Congenital.
Median enrollment 51 across the 18 interventional studies, 71 across the 14 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 32 have an industry lead sponsor. The 10 most frequent:
Izmir Democracy University is the lead sponsor of 78 studies on the registry; 32 are open to participants now.
Izmir Democracy University has 1 study filed under Heart Defects, Congenital — fewer than ten, so there is no comparison to draw.
5 of the studies in Heart Defects, Congenital with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05684562Hacettepe UniversityPulmonary Determinants of Cardiorespiratory Fitness in Fontan Patients | 2026-12-25 |
| NCT06823635Fondation Hôpital Saint-JosephAn International Multicenter Study on Transcatheter Device Closure of Perimembranous Ventricular Septal Defects | 2026-12-31 |
| NCT07564882Baskent UniversityThe Effect of Music and Musical Mobile Interventions on Pain and Physiological Parameters | 2027-04-30 |
| NCT07575451Cukurova UniversityEmpowering Families in Pediatric Cardiovascular Surgery: A RAM-Based Approach | 2027-06-15 |
| NCT07319858Istanbul University - CerrahpasaThe Effect of Using Multifunctional Baby Carrier With Heart Surgery | 2027-08 |
Add all 5 to your calendar (.ics) → With an account.
Among the 32 studies in Heart Defects, Congenital with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the effects of functional inspiratory muscle training on physical performance and quality of life in pediatric patients with congenital heart disease.
Congenital heart disease (CHD) is a common condition in newborns. As a congenital disorder, CHD is the leading cause of infant mortality. Recent advances in medical treatment and surgical procedures have improved survival rates among children with CHD. However, despite these developments, children with CHD may still exhibit muscle weakness, physical inactivity, reduced performance in activities of daily living, and a decline in health-related quality of life. Therefore, this study aims to investigate the effects of functional inspiratory muscle training on physical performance and quality of life in pediatric patients with CHD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The telerehabilitation program will last a total of 8 weeks and will consist of two parts: 4 weeks of inspiratory muscle training and 4 weeks of functional inspiratory muscle training. The training program will be held every day of the week, with 3 of those days conducted under the supervision of a physiotherapist.
Other: Inspiratory Muscle Training · Other: Functional Inspiratory Muscle Training
Participants in this group will continue with their routine daily lives.
Moderate-intensity basic inspiratory muscle training will be provided using a threshold pressure loading device (POWERBreathe) for the first four weeks, starting at 30% of MIP and gradually increasing to 50% depending on the participant's tolerance. The training will be conducted twice daily, 15 minutes in the morning and 15 minutes in the evening, for a total of 30 minutes. With the device, the patient will perform 5-10 deep breathing cycles, then remove the device and perform 3-5 calm breaths to control their breathing. At the end of each day, the physiotherapist will communicate with the patients to assess their progress in the exercise and record it in the exercise log.
Following basic IMT, simultaneous exercises (wall plank, wall lateral bridge, wall bridge, shoulder flexion/abduction, elbow flexion, trunk rotation, squat-stand, standing leg raise, walking) will be performed for 4 weeks. Abdominal muscle activation will be taught at the beginning of the training, and functional exercises, paying attention to abdominal stabilization, will continue throughout the training sessions. Moderate intensity IMT will be applied, starting from 30% of the MIP and increasing up to 50% depending on the participant's tolerance. While using the device, the patient will take 5-10 deep breaths and simultaneously perform the functional exercises in sequence, each with 5-10 repetitions/sets (1-3 sets per day). Then, they will remove the device from their mouth and practice breath control by taking 3-5 calm breaths. Exercises that the patient cannot perform will be recorded.
Inspiratory Muscle Strength
Inspiratory muscle strength will be assessed with a spirometer. The highest value for inspiratory pressure will be recorded.
Time frame: Baseline and after 8-week
Expiratory Muscle Strength
Expiratory muscle strength will be assessed with a spirometer. The highest value for expiratory pressure will be recorded.
Time frame: Baseline and after 8-week
Quality of Life Score
The Pediatric Quality of Life Inventory 3.0 Cardiac Module will be assessed using Turkish versions of the 8-12 and 13-18 year old child and parent forms. A minimum score of 0 and a maximum score of 100 can be obtained on the scale; a higher score indicates a higher quality of life.
Time frame: Baseline and after 8-week
Exercise Capacity measurement
Maximal exercise capacity will be assessed using the Incremental Shuttle Walk Test. The number of shuttles completed after the test will be recorded.
Time frame: Baseline and after 8-week
Measurement of Functional Capacity
Functional capacity will be assessed using the 1-minute sit-to-stand test, and the number of sit-to-stand repetitions performed in one minute will be recorded.
Time frame: Baseline and after 8-week
Grip strength measurement
Grip strength will be measured using a standard, adjustable, and portable hydraulic hand dynamometer.
Time frame: Baseline and after 8-week
Measurement of Back and Leg Strength
Back and leg strength will be measured using a Saehan standard platform back-leg-chest dynamometer. The best value recorded from the dynamometer after three trials will be noted in kilograms.
Time frame: Baseline and after 8-week
Forced vital capacity (FVC)
Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.
Time frame: Baseline and after 8-week
Forced expiratory volume in the first second (FEV1)
Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.
Time frame: Baseline and after 8-week
FEV1/FVC
Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.
Time frame: Baseline and after 8-week
Flow rate 25-75% of forced expiratory volume (FEF 25-75%)
Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.
Time frame: Baseline and after 8-week
Peak flow rate (PEF)
Lung function will be assessed with a spirometer. The highest value of the three measurements will be used and interpreted according to gender, age, weight and height.
Time frame: Baseline and after 8-week
Plan to share: No
Start is estimated for Oct 2026; primary completion for Jun 2028, 20 months later.
Of 208 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 20 months is below that.
Counting every sponsor, half of 226 studies reached it within 34 months; a quarter within 17 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Izmir Democracy University